Medical imaging device; small molecule for neurological disorder

Terran Biosciences is focused on developing innovative therapeutics and technologies aimed at addressing neurological and psychiatric disorders. Their portfolio includes a late-stage therapy for schizophrenia, which combines xanomeline and trospium prodrugs to facilitate once-daily oral dosing and long-acting injections. Additionally, they are advancing selective serotonin 2A receptor antagonists, such as Eplivanserin and Volinanserin, which have been tested in extensive clinical trials. These compounds are being developed to treat various neuropsychiatric conditions, including Parkinson's psychosis, while also exploring fixed-dose combinations with psychedelics to enhance therapeutic efficacy without inducing hallucinations.

In addition to their drug development efforts, Terran is pioneering AI-enabled medical software, specifically NM-101, a cloud-based platform designed for analyzing neuromelanin MRI scans. This technology, which has received FDA clearance, allows for rapid analysis and reporting, providing valuable insights into neurological conditions associated with neuromelanin. Terran's commitment to advancing psychedelic therapies, including novel prodrugs and improved psychoplastogens, positions them as a leader in the burgeoning field of neuroscience, with a focus on enhancing patient care and treatment accessibility.

United States

Terran Biosciences is a biotech platform company devoted to the development of therapeutics and technologies for patients with neurological and psychiatric diseases. Their portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled first-in-class and best-in-class psychedelic therapies, and an AI-enabled imaging software platform.

Terran Biosciences

Company Details